Breast Cancer

Genentech is seeking the FDA's approval to offer T-DM1 for patients with HER2-positive metastatic breast cancer amid updated results from the pivotal EMILIA trial showing significantly improved OS.

Dr. Louis Weiner, from the Lombardi Comprehensive Cancer Center, Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer.

A "substantial minority" of radiation oncologists report that surgeons fail to include them in the breast cancer treatment decision-making process before definitive surgery.

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.

Dr. Julie Gralow from the Seattle Cancer Care Alliance Discusses T-DM1-Induced Thrombocytopenia

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Two phase III studies presented at ASCO 2012 explored the role of lapatinib in the treatment of HER2-positive breast cancer.

The FDA has approved everolimus for treating patients with hormone receptor-positive, HER2 negative breast cancer, when given in combination with the aromatase inhibitor exemestane.

The long-standing debate about postmenopausal hormones and breast cancer gained more evidence to support an increased cancer risk.

Women who have been previously treated for early-stage breast cancer are much less likely to complain of hot flashes if they remain within 10% of their prediagnosis weight.

Breast cancer survival improved significantly in patients who increased consumption of cruciferous vegetables following diagnosis, a study of Chinese women showed.

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints

Young women who have recently used DMPA for at least 1 year have more than twice the risk of invasive breast cancer as young women who do not report recent use of the injectable contraceptive.

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

The FDA has approved pertuzumab combined with trastuzumab and docetaxel for patients who have not received prior treatment for HER2-positive metastatic breast cancer.

Dr. José Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.